Quick Facts
  • Primary Location:
    Tennessee Oncology
  • Expertise:
    Chemotherapy
    Bone Marrow Biopsies
  • Speciality:
    Hematology
  • Gender:
    Male
  • Language:
    English
  • Med School:
    American University

Get to Know Dr. Michel E. Kuzur

Medical oncologist Dr. Michel E. Kuzur has been caring for cancer patients for four decades, combining his vast experience with the latest clinical research to provide first-rate, personalized treatment for his patients.

Since 1994, Kuzur has been with Tennessee Oncology, one of the country’s largest community based cancer-care groups. The group has a growing network of top-level physicians.

Kuzur sees patients at the TriStar Skyline Medical Center and the TriStar Centennial Medical Center in Nashville. He treats many different adult malignancies, including lung cancer, mesothelioma, kidney cancer, prostate cancer and Hodgkin’s lymphoma.

He has been practicing medicine since 1981 and has played a key role in Tennessee Oncology’s reputation for high-quality care and expertise in clinical research.

Contact Michel Kuzur

Specialties of Dr. Michel E. Kuzur

  • Medical oncology
  • Hematology
  • Lung cancer
  • Chemotherapy
  • Bone marrow biopsies

Dr. Michel E. Kuzur’s Experience and Medical Education

  • Tennessee Oncology
  • Miller Medical Group
  • University of Massachusetts Memorial Hospital (Residency)
  • Vanderbilt University Medical Center (Fellowship)
  • American University of Beirut (Internship and M.D.)

Awards and Other Recognitions

  • Patients’ Choice Award
  • Nashville Academy of Medicine (Member)
  • American Society of Clinical Oncology (Member)
  • American Society of Hematology (Member)

Publications of Dr. Michel E. Kuzur

  • Bendell, J. et al. (2017, April). A Phase-2 Trial of Single Agent Axitinib as Maintenance Therapy Following First-Line Treatment With Modified FOLFOX/Bevacizumab in Patients With Metastatic Colorectal Cancer. Cancer Investigation.
  • Kuzur, M. et al. (2005, June). Paclitaxel, carboplatin, and gemcitabine (PCG) versus gemcitabine and vinorelbine (GV) in chemotherapy naïve patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase III trial of the Minnie Pearl Cancer Research Network (MPCRN). Journal of Clinical Oncology.

Lab technician using a microscope in a lab
COVID-19 and Mesothelioma Presentation
United States one-hundred-dollar bills
Access More than $32 Billion in Trust Funds
Technician documenting notes in a lab
Find Active Mesothelioma Clinical Trials

  •  
  •  
  •  
Tell us what you think
Did this article help you?
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?